

-----:
ORDIN DE PLATA NR.: 2272 TIP.DOC. 1 :
DATA EMITERII:joi, 24 august 202:
=====:
PLATITI: 1400-00 LEI: Una Mie Patru Sute lei 00 bani :
:
:
=====:
PLATITOR: (R) 'BIOSISTEM CONTUL DE PLATI/CODUL IBAN :
MLD" SRL MD95ML000000002251429243 :
CODUL FISCAL :1010600028048 / :
:
:
=====:
PRESTATORUL PLATITOR CODUL BANCII:
BC"Moldindconbank"S.A. fil."Invest" Chisinau :MOLDMD2X329:
=====:
BENEFICIAR (R) IMSP Spital CONTUL DE PLATI/CODUL IBAN :
ul Clinic al Ministerului San MD05ML000000002251512149 :
atatii CODUL FISCAL :1003600150716 / :
:
:
=====:
PRESTATORUL BENEFICIAR CODUL BANCII:
BC"Moldindconbank"S.A. :MOLDMD2X :
=====:
DESTINATIA PLATII: Pentru garantia pentru: TIPUL TRANSFERULUI :
oferta la procedura de achizitie public: NORMAL/URGENT :N:
a nr. ocds-b3wdp1-MD-1692367387494 din 2: :
4.08.2023 : :
: :
: L.S. :
=====:
CODUL TRANZACTIEI:001: :
DATA PRIMIRII:24/08/2023 : SEMNATURILE :
DATA EXECUTARII: : EMITENTULUI :
-----:
CONducATOR:Web Poiata Vitalie :
MIIGYwYJKoZIhvcNAQcCoIIGVDCcBlACAQExCzAJBgUrDgMCGGUAMAsGCSqGSIB:
DQEHAaCCBGwggRoMIIDUKADAgECAhNHAACjbilrgFksQ0G4AAAAAKNuMA0GCSq:
SIB3DQEBCwUAMCIxIDAeBgNVBAMTF0NFU1QxLUNBLU1vbGRpbmRjb25iYW5rMB4:
DTIxMDEyODExMzgwNVVoXDTI0MDEyODExNDgwNVowgZ8xCzAJBgNVBAYTAk1EMRA:
gYDVQQIEwdNb2xkb3ZhmREwDwYDVQQHEwhDaGlzaW5hdTEWMBQGA1UEChMNQml :
:
(semnatura electronica) :
CONTABIL-SEF:Web Nasedchin Alexandr :
MIIGZwYJKoZIhvcNAQcCoIIGWDCcBlQCAQExCzAJBgUrDgMCGGUAMAsGCSqGSIB3:
DQEHAaCCBHAWggRsMIIDVKADAgECAhNHAACjcahRKqbJeg8QAAAAAKNxMA0GCSqG:
SIB3DQEBCwUAMCIxIDAeBgNVBAMTF0NFU1QxLUNBLU1vbGRpbmRjb25iYW5rMB4X:
DTIxMDEyODExMzkwOFoXDTI0MDEyODExNDkxOFowgaMxCzAJBgNVBAYTAk1EMRAw:
YDVQQIEwdNb2xkb3ZhmREwDwYDVQQHEwhDaGlzaW5hdTEWMBQGA1UEChMNQmlv :
:
L.S. (semnatura electronica) :
CONducATOR: :
(semnatura manuala) :
CONTABIL-SEF: :
(semnatura manuala) :
SEMnATURA PRESTATORUL L.S. :
:
MOTIVUL REFUZULUI : L.S. :
-----:

► **Test Items:**

Category	Test Item	Specimen Type	Sample Volume	Reaction Time	Measuring Range
Diabetes	HbA1c	WB	5μL	15min	3.0-14.0%
Inflammation	CRP	S/P/WB	5μL	3min	0.5-200μg/mL
	PCT	S/P/WB	100μL	10min	0.1-50ng/mL
	SAA	S/P/WB	5μL	15min	2.0-300μg/mL
Cardiac	CK-MB	S/P/WB	100μL	10min	2.0-80ng/mL
	cTnl	S/P/WB	100μL	10min	0.05-40ng/mL
	Myo	S/P/WB	100μL	10min	20-500ng/mL
	NT-proBNP	S/P/WB	100μL	15min	50-25000pg/mL
	D-Dimer	P/WB	100μL	10min	0.1-10μg/mL
	H-FABP	S/P/WB	100μL	15min	1-120ng/mL
Hormone	T3	S/P/WB	100μL	15min	0.5-10nmol/L
	T4	S/P/WB	100μL	10min	10-350nmol/L
	TSH	S/P/WB	100μL	15min	0.1-60μIU/mL
	25-OH-VD	S/P	100μL	10min	5-70ng/mL
	β-HCG	S/P/WB	50μL	15min	2-20000mIU/mL
	LH	S/P/WB	100μL	15min	5-200mIU/mL
	FSH	S/P/WB	100μL	10min	1-150mIU/mL
	GH	S/P/WB	100μL	10min	0.05-100ng/mL
	PRL	S/P/WB	100μL	10min	1-100ng/mL
	AMH	S/P/WB	100μL	10min	0.1-50ng/mL
Gastric Function	PGI	S/P/WB	100μL	10min	10-60ng/mL
	PGII	S/P/WB	100μL	10min	5-100ng/mL
	G-17	S/P/WB	100μL	10min	5-300ng/mL
Renal Function	NGAL	S/P/WB/Urine	100μL	10min	50-5000ng/mL
	mAlb	Urine	100μL	5min	10-200mg/L
	β2-MG	S/P/WB	10μL	10min	0.5-20mg/L
	Cys-C	S/P/WB	10μL	5min	0.5-10ng/L
Tumor	PSA	S/P/WB	100μL	10min	0.1-100ng/mL

# LS-1100

## Dry Fluorescence Immunoassay Analyzer (Portable)



Quantitative

Rapid

Sensitive

Reliable

Accurate, Anytime and Anywhere

New items are available soon!

**Lansion Biotechnology Co., Ltd.**

Add: No.2 Qiande Road, Jiangning District, Nanjing, China

E-mail: biz@lansionbio.com

Web: en.lansionbio.com

Tel: +86-25-5857 7600

Fax: +86-25-5875 8600



Lansion Biotechnology Co., Ltd.

# LS-1100 Dry Fluorescence Immunoassay Analyzer (Portable)

## ► Analyzer Introduction:

LS-1100 uses the advanced method of Time-resolved Fluorescence Immunoassay (TRFIA), for the in-vitro quantitative detection of bio-markers for Diabetes Mellitus, Inflammation, Cardiovascular Diseases, Hormone, Gastric Diseases, Renal Diseases, Tumor, etc.

Application: Laboratory, ER, Cardiology, ICU, Respiratory, Pediatrics, etc.


## ► Features:



“ **Quantitative, Rapid and High Sensitive  
Reliable Result (QC system, QR code calibration)** ”


<b>Method</b>	Time-resolved Fluorescence Immunoassay (TRFIA)
<b>Specimen</b>	Serum/Plasma/Whole Blood/Urine
<b>Weight</b>	1.3kg
<b>Dimensions</b>	225mm × 152mm × 105mm (L×W×H)
<b>Screen</b>	7 inch touch screen
<b>Data Storage</b>	≥ 5000
<b>Printer</b>	Built-in thermal printer
<b>Battery</b>	Built-in lithium battery (super standby time)
<b>Communication</b>	RS232(LIS/HIS), RJ45, USB, WIFI, Bluetooth

## ► Time-resolved Fluorescence Immunoassay (TRFIA) Method:



TRFIA is super-sensitive detection technique characterized by specific fluorescence of rare earth ions. It is not only highly sensitive, but also overcomes the instability of enzyme marker and is the best choice for immunological detection. The high fluorescence intensity and long life of labeled ionic chelates are beneficial to eliminate the influence of fluorescent substances in samples and environment on the test results.

## ► Easy Operation:





## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- LS-1100 Dry Fluorescence Immunoassay Analyzer

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016

EN ISO 18113-3:2011

EN 13612:2002

ISO 14971:2019

EN 13641:2002

ISO 23640:2015

EN ISO 18113-1:2011

ISO 15223-1:2016

EN 62366-1:2015

EN ISO 18113-2:2011

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**

**Position held in the company:** CTO

**Date:** 07/23/2020

**Seal/Stamp:**

**Lansion Biotechnology Co., Ltd.**



Place: Nanjing,China



## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- LS-2100 Dry Fluorescence Immunoassay Analyzer

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016

EN ISO 18113-3:2011

EN 13612:2002

ISO 14971:2019

EN 13641:2002

ISO 23640:2015

EN ISO 18113-1:2011

ISO 15223-1:2016

EN 62366-1:2015

EN ISO 18113-2:2011

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**

**Position held in the company:** CTO

**Date:** 07/23/2020

**Seal/Stamp:**

**Lansion Biotechnology Co., Ltd.**



Place: Nanjing,China



## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- LS-4000 Dry Fluorescence Immunoassay Analyzer (Handheld)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016

EN ISO 18113-3:2011

EN 13612:2002

ISO 14971:2019

EN 13641:2002

ISO 23640:2015

EN ISO 18113-1:2011

ISO 15223-1:2016

EN 62366-1:2015

EN ISO 18113-2:2011

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**

**Position held in the company:** CTO

**Date:** 07/23/2020

**Seal/Stamp:**

**Lansion Biotechnology Co., Ltd.**

Place: Nanjing,China



## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- cTnI Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016

EN ISO 18113-3:2011

EN 13612:2002

ISO 14971:2019

EN 13641:2002

ISO 23640:2015

EN ISO 18113-1:2011

ISO 15223-1:2016

EN 62366-1:2015

EN ISO 18113-2:2011

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**

**Position held in the company:** CTO

**Date:** 07/23/2020

**Seal/Stamp:**

**Lansion Biotechnology Co., Ltd.**

Place: Nanjing,China





## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- CK-MB Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016

EN ISO 18113-3:2011

EN 13612:2002

ISO 14971:2019

EN 13641:2002

ISO 23640:2015

EN ISO 18113-1:2011

ISO 15223-1:2016

EN 62366-1:2015

EN ISO 18113-2:2011

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**  
**Position held in the company:** CTO

**Date:** 07/23/2020

**Seal/Stamp:**

Lansion Biotechnology Co., Ltd.

Place: Nanjing,China



## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- Myo Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016

EN ISO 18113-3:2011

EN 13612:2002

ISO 14971:2019

EN 13641:2002

ISO 23640:2015

EN ISO 18113-1:2011

ISO 15223-1:2016

EN 62366-1:2015

EN ISO 18113-2:2011

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**  
**Position held in the company:** CTO

**Date:** 07/23/2020

**Seal/Stamp:**

Lansion Biotechnology Co., Ltd.

Place: Nanjing,China



## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- NT-proBNP Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**  
**Position held in the company:** CTO

**Date:** 07/23/2020

**Seal/Stamp:**

**Lansion Biotechnology Co., Ltd.**

Place: Nanjing,China



## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- D-Dimer Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**  
**Position held in the company:** CTO

**Date:** 07/23/2020

**Seal/Stamp:**

**Lansion Biotechnology Co., Ltd.**

Place: Nanjing,China



## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- CRP Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**  
**Position held in the company:** CTO

**Date:** 07/23/2020

**Seal/Stamp:**

**Lansion Biotechnology Co., Ltd.**

Place: Nanjing,China



## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- PCT Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**  
**Position held in the company:** CTO

**Date:** 07/23/2020

**Seal/Stamp:**

**Lansion Biotechnology Co., Ltd.**

Place: Nanjing,China







## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- PCT/CRP Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**  
**Position held in the company:** CTO

**Date:** 07/23/2024

**Seal/Stamp:**

Lansion Biotechnology Co., Ltd.

Place: Nanjing,China



## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- SAA Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**  
**Position held in the company:** CTO

**Date:** 07/23/2024

**Seal/Stamp:**

Lansion Biotechnology Co., Ltd.

Place: Nanjing,China



## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- SAA/CRP Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

Place: Nanjing,China

**Name of authorized signatory:**  
**Position held in the company:** CTO

**Date:** 07/23/2020

**Seal/Stamp:**

Lansion Biotechnology Co., Ltd.



## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- TT3 Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

Place: Nanjing,China

**Name of authorized signatory:**  
**Position held in the company:** CTO

**Date:** 07/23/2020

**Seal/Stamp:**

Lansion Biotechnology Co., Ltd.





## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- TT4 Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016

EN ISO 18113-3:2011

EN 13612:2002

ISO 14971:2019

EN 13641:2002

ISO 23640:2015

EN ISO 18113-1:2011

ISO 15223-1:2016

EN 62366-1:2015

EN ISO 18113-2:2011

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**

**Position held in the company:** CTO

**Date:** 07/23/2020

**Seal/Stamp:**

**Lansion Biotechnology Co., Ltd.**



Place: Nanjing,China



## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- TSH Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016

EN ISO 18113-3:2011

EN 13612:2002

ISO 14971:2019

EN 13641:2002

ISO 23640:2015

EN ISO 18113-1:2011

ISO 15223-1:2016

EN 62366-1:2015

EN ISO 18113-2:2011

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**

**Position held in the company:** CTO

**Date:** 07.02.2020

**Seal/Stamp:**

**Lansion Biotechnology Co., Ltd.**



Place: Nanjing,China



## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- AMH Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**  
**Position held in the company:** CTO

**Date:** 07/23/2020

**Seal/Stamp:**

Lansion Biotechnology Co., Ltd.

Place: Nanjing,China



## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- 25-OH-VD Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**  
**Position held in the company:** CTO

**Date:** 07/23/2020

**Seal/Stamp:**

Lansion Biotechnology Co., Ltd.

Place: Nanjing,China



## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- HbA1c Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**  
**Position held in the company:** CTO

**Date:** 07/23/2020

**Seal/Stamp:**

Lansion Biotechnology Co., Ltd.



Place: Nanjing,China



## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- $\beta$ -HCG Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**  
**Position held in the company:** CTO

**Date:** 07/23/2020

**Seal/Stamp:**

Lansion Biotechnology Co., Ltd.



Place: Nanjing,China



## DECLARATION OF CONFORMITY

**According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.**

**Manufacturer:** Lanson Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- LH Test Kit (Dry Fluorescence Immunoassay)

**Category:** Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**  
**Position held in the company:** CTO

**Date:** 04.02.2020

**Seal/Stamp:**

**Lanson Biotechnology Co., Ltd.**



Place: Nanjing, China



## DECLARATION OF CONFORMITY

**According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.**

**Manufacturer:** Lanson Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- FSH Test Kit (Dry Fluorescence Immunoassay)

**Category:** Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**  
**Position held in the company:** CTO

**Date:** 04.02.2020

**Seal/Stamp:**

**Lanson Biotechnology Co., Ltd.**



Place: Nanjing, China

CE

## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- PRL Test Kit (Dry Fluorescence Immunoassay)

**Category:** Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**  
**Position held in the company:** CTO

**Date:** 09.02.2020

**Seal/Stamp:**

Lansion Biotechnology Co., Ltd.



Place: Nanjing,China

CE

## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- 25-OH-VD3 Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**  
**Position held in the company:** General Manager

**Date:** 28/03/2021

**Seal/Stamp:**

Lansion Biotechnology Co., Ltd.



Place: Nanjing,China



## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- BNP Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**

**Position held in the company:** General Manager

**Date:** 25/03/2021

**Seal/Stamp:**

Lansion Biotechnology Co., Ltd.

Place: Nanjing,China



## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- H-FABP Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**

**Position held in the company:** General Manager

**Date:** 25/03/2021

**Seal/Stamp:**

Lansion Biotechnology Co., Ltd.

Place: Nanjing,China



CE

## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- IL-6 Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:


**Name of authorized signatory:**  
**Position held in the company:** General Manager

**Date:** 25/03/2021

**Seal/Stamp:**

Lansion Biotechnology Co., Ltd.

Place: Nanjing,China



CE

## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- hs-cTnI Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:


**Name of authorized signatory:**  
**Position held in the company:** General Manager

**Date:** 08/05/2021

**Seal/Stamp:**

Lansion Biotechnology Co., Ltd.

Place: Nanjing,China





## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- Ferritin Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**  
**Position held in the company:** General Manager

**Date:** 2021/05/18

**Seal/Stamp:**

Lansion Biotechnology Co., Ltd.

Place: Nanjing,China



## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province, PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- PGI/PGII Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:


**Name of authorized signatory:**  
**Position held in the company:** General Manager

**Date:** 2021/05/18

**Seal/Stamp:**

Lansion Biotechnology Co., Ltd.

Place: Nanjing,China





## DECLARATION OF CONFORMITY

According Directive 98/79/EC on in vitro diagnostic medical devices, Annex III.

**Manufacturer:** Lansion Biotechnology Co., Ltd.

**Address:** No.2,Qiande Road,Science Park,Jiangning District,210000 Nanjing,Jiangsu Province,  
PEOPLE'S REPUBLIC OF CHINA.

**European Representative:** Lotus NL B.V.

**Contact person:** Peter E-mail: peter@lotusnl.com

**Address:** Koningin Julianaplein 10,1e Verd, 2595AA, The Hague, Netherlands.

### In Vitro Diagnostic Directive:

- PCT/IL-6 Test Kit(Dry Fluorescence Immunoassay)

**Category:**Others.

**Conformity assessment route:** Declaration of Conformity IVDD Annex III.

### Applicable Standards:

ISO 13485:2016	EN ISO 18113-3:2011	EN 13612:2002
ISO 14971:2019	EN 13641:2002	ISO 23640:2015
EN ISO 18113-1:2011	ISO 15223-1:2016	EN 62366-1:2015
EN ISO 18113-2:2011		

We, the manufacturer, here declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices.

We agree to develop, implement and maintain a documented post-production monitoring process.

Signed on:

**Name of authorized signatory:**


**Position held in the company:** General Manager

**Date:** 12/08/2021

**Seal/Stamp:**

**Lansion Biotechnology Co., Ltd.**

Place: Nanjing,China



## cTnI Test Kit User Manual

(Dry Fluorescence Immunoassay)

### [PRODUCT NAME]

cTnI Test Kit (Dry Fluorescence Immunoassay)

### [PACKAGE SPECIFICATION]

- 1 test/kit
- 5 tests/kit
- 25 tests/kit
- 50 tests/kit
- 100 tests/kit

### [INTENDED USE]

cTnI Test Kit (Dry Fluorescence Immunoassay) is intended for in-vitro quantitative measurement of cTnI (Cardiac Troponin I) in serum and plasma. This test is used as an aid in the diagnosis of myocardial injury such as Acute Myocardial Infarction (AMI), Unstable Angina, Acute Myocarditis and Acute Coronary Syndrome (ACS).

### [TEST PRINCIPLE]

cTnI Test Kit (Dry Fluorescence Immunoassay) uses the principle of antigen-antibody reaction. The testing sample will migrate forward due to capillary action, then the cTnI of the sample will combine with antibody which is attached to fluorescence microspheres. This marked complex is attached to the detection area of immobilized antibody and the other fluorescence microspheres are attached to the control area.

When the test strip is inserted into the analyzer, the analyzer automatically scans two ribbons and detected the fluorescence intensity of the composite emission from the testing area and the control area. The ratio of the two fluorescence values was used to calculate the content of the detected substances.

### [MAIN COMPONENTS]

1. cTnI test strip in a sealed pouch with desiccant.....25 tests
2. QR code card for calibration.....1 piece
3. User Manual.....1 piece
4. Quantitative suction and dropping tube (Optional).

**Note: Do not mix or interchange different batches of kit.**

### [STORAGE AND VALIDITY]

Store the test kit at 4°C-30°C, with a valid period of 18 months.  
Test strip should be used within 30 minutes once the foil pouch is opened.

### [APPLICABLE DEVICES]

1. FIC-S100 Dry Fluorescence Immunoassay Analyzer
2. LS-1000 Dry Fluorescence Immunoassay Analyzer
3. LS-2000 Dry Fluorescence Immunoassay Analyzer
4. LS-1100 Dry Fluorescence Immunoassay Analyzer
5. LS-2100 Dry Fluorescence Immunoassay Analyzer
6. LS-4000 Hand-Held Dry Fluorescence Immunoassay Analyzer
7. LS-7000 Microfluidic and Dry Fluorescence Immunoassay Analyzer

### [SAMPLE REQUIREMENT]

1. Used for human **serum and plasma**. Other bodily fluids and samples may not get the accurate result.
2. Plasma can be anticoagulant with heparin and sodium citrate under aseptic conditions.
3. At room temperature, the test should be performed within 4 hours after the sample collection.
4. Serum or plasma sample can be stored at 2°C-8°C for 3 days at most. If more than 3 days, it should be stored at -20°C. It is suggested to use fresh sample to test. Stale blood sample may not get accurate result.
5. The sample before testing should be recovered to room temperature (15°C-30°C).
6. **Sample Volume: 100µL**

### [TEST PROCEDURE]

1. Collect samples according to user manual.
2. Before the test, the sample and test strip should be recovered to room temperature (15°C-30°C).

#### **For LS-1100**

3. Perform QR code calibration when necessary. (Details refer to LS-1100 User Manual)
  4. On the main interface of LS-1100, press “Test” icon to enter testing interface. Input patient information, sample information, doctor information when necessary. (Details refer to LS-1100 User Manual)
  5. Remove test strip from sealed pouch and put it on a clean table, horizontally placed.
  6. Using pipette to drop 100µL sample into the sample port in the test strip.
  7. **Reaction Time: 10 minutes**
- For panel inside: Insert the test strip into the analyzer immediately after sample dispensing. Then click “Test”.
- For panel outside: After reaction time 10 minutes is elapsed, insert the test strip into the analyzer and then click “Test”.
8. The result will be shown on the screen and printed automatically.

**Notes: It is required to perform QR code calibration when starting to use one new batch of kit.**

### [EXPECTED VALUE]

#### **Cut-Off Value: 0.5ng/mL**

The cut-off value for cTnI was determined by testing samples from 500 apparently healthy individuals. The 99th percentile of the concentration for cTnI is 0.5ng/mL. (The probability that value of a normal person below 0.5ng/mL is 99%.)

It is recommended that each laboratory establish its own reference range for the population it serves.

### [INTERPRETATION OF RESULT]

1. If the test result of the sample is more than 40ng/mL, the analyzer displays “>40ng/mL”, and if the result is less than 0.05ng/mL, the analyzer displays “<0.05ng/mL”. Specific data can be exported through related software as needed.

2. When the sample concentration exceeds the detection limit, the maximum dilution ratio is 3 times when the sample is diluted with calf serum or negative sample.

#### [LIMITATION]

1. This kit is only for the serum and plasma test.
2. The test result of this kit are only one of the diagnostic aids for the clinicians.
3. The result of the test should be evaluated in the context of all the clinical and laboratory data available. In those instances where the laboratory results do not agree with the clinical evaluation, additional tests should be performed accordingly.

#### [PRODUCT PERFORMANCE]

1. Measuring Range: 0.05-40ng/mL.
2. Lower Detection Limit:  $\leq 0.05\text{ng/mL}$ .
3. Accuracy: Verify with comparison experiments, the relative deviation  $\leq 15\%$ , the correlation coefficient  $r \geq 0.990$ .
4. Within-Run Precision:  $\leq 15\%$ .
5. Between-Run Precision:  $\leq 15\%$ .
6. Hook Test: No hook effect with high concentration sample. Hook test was conducted with reference material exceeding the upper limit of linear range, and the detection result was greater than the upper limit of detection.

#### [PRECAUTIONS]

1. Only used for in vitro diagnostics.
2. Do not use the kit beyond the expiration date.
3. After the test strip is removed from the sealed pouch, it should be tested as soon as possible to avoid excessive time in the air, resulting in dampness.
4. Do not reuse the test strip.
5. The damaged test strip or package cannot be used.
6. Do not mix the components of different kits.

#### [REFERENCES]

1. Yang Zhenhua, Pan Baizhong, Xu. Predictors of Chinese Medical Association inspection documents: guidelines for the application of markers of myocardial injury. Chinese Journal of laboratory medicine, 2002, 25 (3): 85.
2. Jin Caining, Xu Guobin, Zhu Lihua, et al. Determination of the biological characteristics of human cardiac TnI and its application in clinical diagnosis. Journal of clinical test, 2002, 20 (2): 18.
3. Department of medical administration, ministry of health. National operational procedures for clinical examination. Southeast university press, 1991.



Lansion Biotechnology Co., Ltd.

Add: No.2, Qiande Road, Jiangning District, Nanjing, China

Tel: 86-25-58577600

Fax: 86-25-58758600

E-mail: biz@lansionbio.com

Website: en.lansionbio.com

EC REP

Llins Service & Consulting GmbH

Address: Am Heiligenhaus 7,69126, Heidelberg, Germany

Tel: +49 176 63866127

Revision Date: May 31, 2019

Version Number: 0.1

Production date and expiration see the label.

## D-Dimer Test Kit User Manual

(Dry Fluorescence Immunoassay)

### [PRODUCT NAME]

D-Dimer Test Kit (Dry Fluorescence Immunoassay)

### [PACKAGE SPECIFICATION]

- 1 test/kit
- 5 tests/kit
- 25 tests/kit
- 50 tests/kit
- 100 tests/kit

### [INTENDED USE]

D-Dimer Test Kit (Dry Fluorescence Immunoassay) is intended for in-vitro quantitative measurement of D-Dimer in human plasma. This test is used as an aid in the assessment and evaluation of patients suspected of deep vein thrombosis (DVT) and pulmonary embolism (PE), diagnosis of disseminated intravascular coagulation (DIC), effective evaluation and monitoring the effect of thrombolytic therapy, diagnosis and assessment of myocardial infarction and cerebral infarction.

### [TEST PRINCIPLE]

D-Dimer Test Kit (Dry Fluorescence Immunoassay) uses the principle of antigen-antibody reaction. The testing sample will migrate forward due to capillary action, then the D-Dimer of the sample will combine with antibody which is attached to fluorescence microspheres. This marked complex is attached to the detection area of immobilized antibody and the other fluorescence microspheres are attached to the control area. When the test strip is inserted into the analyzer, the analyzer automatically scans two ribbons and detected the fluorescence intensity of the composite emission from the testing area and the control area. The ratio of the two fluorescence values was used to calculate the content of the detected substances.

### [MAIN COMPONENTS]

1. D-Dimer test strip in a sealed pouch with desiccant.....25 tests
2. Sample diluent.....25 pieces
3. QR code card for calibration.....1 piece
4. User Manual.....1 piece
5. Quantitative suction and dropping tube (Optional).

**Note: Do not mix or interchange different batches of kit.**

### [STORAGE AND VALIDITY]

Store the test kit at 4°C-30°C, with a valid period of 18 months.  
Test strip should be used within 30 minutes once the foil pouch is opened.

### [APPLICABLE DEVICES]

1. FIC-S100 Dry Fluorescence Immunoassay Analyzer
2. LS-1000 Dry Fluorescence Immunoassay Analyzer
3. LS-2000 Dry Fluorescence Immunoassay Analyzer

4. LS-1100 Dry Fluorescence Immunoassay Analyzer
5. LS-2100 Dry Fluorescence Immunoassay Analyzer
6. LS-4000 Hand-Held Dry Fluorescence Immunoassay Analyzer
7. LS-7000 Microfluidic and Dry Fluorescence Immunoassay Analyzer

### [SAMPLE REQUIREMENT]

1. Used for human **plasma**. Other bodily fluids and samples may not get the accurate result.
2. Plasma sample can be anticoagulant with heparin and sodium citrate under aseptic conditions.
3. At room temperature, the test should be performed within 4 hours after the sample collection.
4. Plasma sample can be stored at 2°C-8°C for 3 days at most. If more than 3 days, it should be stored at -20°C. It is suggested to use fresh sample to test. Stale blood sample may not get accurate result.
5. The sample before testing should be recovered to room temperature (15°C-30°C).
6. **Sample Volume: 100µL**

### [TEST PROCEDURE]

1. Collect samples according to user manual.
2. Before the test, the sample and test strip should be recovered to room temperature (15°C-30°C).

#### For LS-1100

3. Perform QR code calibration when necessary. (Details refer to LS-1100 User Manual)
4. On the main interface of LS-1100, press "Test" icon to enter testing interface. Input patient information, sample information, doctor information when necessary. (Details refer to LS-1100 User Manual)
5. Remove test strip from sealed pouch and put it on a clean table, horizontally placed.
6. Using pipette to deliver 100µL sample into one tube of sample diluent. Mix gently and thoroughly. And then drop 100µL of mixed fluid into the sample port in the test strip.

#### **7. Reaction Time: 10 minutes**

For panel inside: Insert the test strip into the analyzer immediately after sample dispensing. Then click "Test".

For panel outside: After reaction time 10 minutes is elapsed, insert the test strip into the analyzer and then click "Test".

8. The result will be shown on the screen and printed automatically.

**Notes: It is required to perform QR code calibration when starting to use one new batch of kit.**

### [EXPECTED VALUE]

#### **Cut-Off Value: 0.5µg/mL**

D-Dimer concentration is determined using samples obtained from 200 apparently healthy individuals.

It is recommended that each laboratory establish its own reference range for the population it serves.

**[INTERPRETATION OF RESULT]**

1. If the test result of the sample is more than 10 $\mu$ g/mL, the analyzer displays ">10 $\mu$ g/mL", and if the result is less than 0.1 $\mu$ g/mL, the analyzer displays "<0.1 $\mu$ g/mL". Specific data can be exported through related software as needed.
2. When the sample concentration exceeds the detection limit, the maximum dilution ratio is 3 times when the sample is diluted with calf serum or negative sample.

**[LIMITATION]**

1. This kit is only for plasma.
2. The test result of this kit are only one of the diagnostic aids for the clinicians.
3. The result of the test should be evaluated in the context of all the clinical and laboratory data available. In those instances where the laboratory results do not agree with the clinical evaluation, additional tests should be performed accordingly.

**[PRODUCT PERFORMANCE]**

1. Measuring Range: 0.1-10 $\mu$ g/mL.
2. Lower Detection Limit:  $\leq$ 0.1 $\mu$ g/mL.
3. Accuracy: Verify with comparison experiments, the relative deviation  $\leq$ 15%, the correlation coefficient  $r \geq$ 0.990.
4. Within-Run Precision:  $\leq$ 15%.
5. Between-Run Precision:  $\leq$ 15%.
6. Hook Test: No hook effect with high concentration sample. Hook test was conducted with reference material exceeding the upper limit of linear range, and the detection result was greater than the upper limit of detection.

**[PRECAUTIONS]**

1. Only used for in vitro diagnostics.
2. Do not use the kit beyond the expiration date.
3. After the test strip is removed from the sealed pouch, it should be tested as soon as possible to avoid excessive time in the air, resulting in dampness.
4. Do not reuse the test strip.
5. The damaged test strip or package cannot be used.
6. Do not mix the components of different kits.

**[REFERENCES]**

1. Xu guanghai, Chen lixia. Experimental evaluation of quantitative determination of plasma d-dimer[J]. Chinese Journal of Misdiagnosis. 2010, 10(09): 2064-2065.
2. Chen jiuyan. Detection of d-dimer and its application in the diagnosis and treatment of thrombotic diseases. Shanxi Journal of Medicine. 2008, 37(24): 1123-1125.



Lansion Biotechnology Co., Ltd.

Add: No.2, Qiande Road, Jiangning District, Nanjing, China

Tel: 86-25-58577600

Fax: 86-25-58758600

E-mail: biz@lansionbio.com

Website: en.lansionbio.com



Llins Service & Consulting GmbH

Address: Am Heiligenhaus 7,69126, Heidelberg, Germany

Tel: +49 176 63866127

Revision Date: May 31, 2019

Version Number: 0.1

Production date and expiration see the label.